Aug 11, 2021

Yusen Logistics Transported AstraZeneca's COVID-19 Vaccine

Yusen Logistics Co., Ltd. (President: Toru Kamiyama) was responsible for the international transportation of the COVID-19 vaccine of AstraZeneca Co., Ltd. (headquartered in Kita-ku, Osaka) provided to Taiwan, Vietnam, Indonesia, Thailand, the Philippines, and Malaysia through the Japanese government, from Japan to each country and region.

 

Yusen Logistics has invested heavily over the past 20 years in developing specialist new services and resources in global healthcare supply chain, and we meet a broad range of needs with safe and high-quality services that meet global standards.

We have established pharmaceutical specialist teams in Japan, Americas, Europe, East Asia, and South Asia and Oceania to strengthen healthcare and pharmaceutical logistics globally.

In 2016, Yusen Logistics (Benelux) B.V. became the first Japanese air freight forwarder at Amsterdam Schiphol Airport to be awarded the prestigious IATA-CEIV Pharma⁽*¹⁾ certification. In Asia, PT. Yusen Logistics Indonesia became the first logistics business in Indonesia to acquire GDP⁽*²⁾ certification at Soekarno–Hatta International Airport in 2016.

In Japan, we were the first Japanese air freight forwarder at Kansai International Airport to acquired IATA-CEIV Pharma certification in 2018 and acquired CEIV Pharma certification at Narita International Airport in 2021.

In addition, our group is expanding operation bases complying with GDP in each country, with the aim of building a network of high-quality pharmaceutical logistics services that meet consistent standards and assure product integrity. Currently, a total of 39 operation bases in 24 countries and regions around the world are compliance with our global GDP standards.

 

In the transportation of Healthcare products, including this time transportation of the COVID-19 vaccine, we have prepared several backup plans that guarantee quality, such as routings and plants, and have formulated the optimal plan after carrying out route risk assessments to mitigate any future risks we may foresee.

As transportation and management of this vaccine is required to maintain a cold storage(2–8°C), we were able to realize safe and reliable transportation to each country and region through cooperation with partner companies.

We will continue to place top priority on ensuring the safety of healthcare products with quality-first services through appropriate transportation by meeting compliance regulations of each country.

 

Partner companies (in random order)

Japan Airlines Co., Ltd., All Nippon Airways Co., Ltd., Narita International Airport Corporation, International Air Cargo Terminal Co., Ltd., Kohku Shuhai Service Co., Ltd., Oosumi Logistics Co., Ltd., Akaumi Co., Ltd.

 

⁽*¹⁾ CEIV Pharma (the Center of Excellence for Independent Validators in Pharmaceutical Logistics)

⁽*²⁾ GDP (Good Distribution Practice)

 

 

Transportation scene

 


The news on this website is as of the date announced and may change without notice.